Sichenzia Ross Ference Carmel LLP Represents Genetic Technologies Limited in a $2 Million Registered Direct Offering and Concurrent Private Placement

New York, NY – April 22, 2024 – Sichenzia Ross Ference Carmel LLP announced today that it represented Genetic Technologies Limited (ASX:GTG; NASDAQ:GENE, “Company”) in a $2 million registered direct offering and private placement.

The Company issued an aggregate of 1,000,000 American Depositary Shares (“ADSs”) (or ADS equivalents in lieu thereof), each representing 30 ordinary shares of the Company, at an offering price of $2.00 per ADS. In addition, the Company has issued unregistered warrants to purchase up to 1,000,000 ADSs. The warrants have an exercise price of $2.00 per ADS, are exercisable upon issuance and will expire five years following issuance.

The Sichenzia Ross Ference Carmel LLP team was led by partners Darrin M. Ocasio and Avital Perlman and associate Mayank Pradhan.